H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 12.8% of adults in Oxnard have diagnosed diabetes — 0.8 points above the U.S. 12% figure. Census population 202,063. California Medicare wound biologics: Noridian Healthcare Solutions (JE). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed Oxnard clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a Oxnard storefront.
Platelet Rich Plasma (PRP) Therapy in Oxnard, CA for clinics & physicians. PRP therapy systems with 1-minu… Compliance support & pricing — contact Hawk Medical.
Oxnard is a city under 250k (202,063 Census). CDC PLACES (2023, crude) estimates 12.8% of adults in Oxnard have diagnosed diabetes — 0.8 points above the U.S. 12% figure. Adult arthritis here is 17.6% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Keep 361 tissue, autologous PRP, and skin substitutes on different tickets. We onboard against that split — then ship.
National Platelet Rich Plasma (PRP) Therapy notes (how the product actually works)America’s Health Rankings (BRFSS 2024) only publishes state diabetes as a range nationally (Colorado 8.4% to West Virginia 18.4%). For Oxnard we use CDC PLACES instead of interpolating a fake city rate from that range. CDC PLACES (2023, crude) estimates 12.8% of adults in Oxnard have diagnosed diabetes — 0.8 points above the U.S. 12% figure.
If you already buy platelet rich plasma therapy elsewhere, use this page as a check: homologous-use language, current Noridian Healthcare Solutions article IDs, and PLACES 12.8% diabetes as the epidemiologic floor. If that is how you already practice, the catalog will fit.
CDC PLACES (2023, crude prevalence) estimates 12.8% of adults — 0.8 points above the U.S. 12% figure. Obesity is 28.4%; arthritis is 17.6%. That is place-level BRFSS modeling, not a clinic census and not a Oxnard trial.
The allograft is used to perform the same basic function in the recipient as in the donor (FDA 361). Using umbilical or amniotic tissue as a marketed “stem cell cure” for unrelated conditions is outside that lane and is a California compliance risk.
The 96.5% figure is a product-level clinical experience statistic published on our wound-care materials — not a city-specific trial. Your outcomes will depend on patient selection, offloading, and follow-up.
Often yes, which is the point of vendor consolidation. Keep DME delivery tickets and HCT/P lot files separate so a California audit trail stays clean.
Ask for the IFU, the lot-traceability packet, and the Noridian Healthcare Solutions article IDs for the codes you actually bill. If the sales sheet cannot produce those, do not put it in a Oxnard fridge. That is how an account with us starts.
Contact us to learn how Hawk Medical supports practices in Oxnard, CA.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for Oxnard is JE geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for Oxnard — 0.8 points above the U.S. 12% figure. Planning input, not an outcomes claim.
California Part B wound biologics follow this contractor (siblings: HI, NV). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in Oxnard. Useful for joint-program math; still needs a diagnosis and privileging.
No Oxnard storefront. Joe Bradley is an active practice owner. platelet rich plasma therapy stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.